Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 prophylaxis (excluding children) meta-analysis

Accorsi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
-/- no results
    Comparison of 2 Doses vs Unvaccinated by Time Since Vaccination (graphical presentation) : The upper bound of the 95% CI was consistently greater than 1 starting at 3 months after second dose for BNT162b2 and at 6 months after second dose for mRNA-1273
    Mattiuzzi OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 85 % decrease in confirmed COVID (any severity)
    • suggested 85 % decrease in hospitalization
    Ontario (Buchan) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 37 % decrease in confirmed COVID (any severity)
    Tenforde OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 97 % decrease in confirmed COVID (any severity)
    England (Andrews) OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
    		581/130867 suggested
    • suggested 75 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
    • suggested 71 % decrease in symptomatic Covid-19,confirmed COVID (any severity)
    Sisonke 2 (booster)
          NCT05148845    		 OBSfirst booster dosecontrolCOVID-19 prophylaxis (excluding children)NA
    		-/- suggested
    • suggested 85 % decrease in hospitalization

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons